CLOs on the Move

Hookipa Pharma

www.hookipapharma.com

 
Hookipa Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body`s immune system. HOOKIPA`s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA`s “off-the-shelf” ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

World Wide Webmasters

World Wide Webmasters is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HotSpot Therapeutics

HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.

Antios Therapeutics

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.

Aspira Women`s Health

Aspira Women`s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women`s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.